Ke Liu

Title: Ke Liu: Innovator in Lysosomal Storage Disorder Treatments

Introduction

Ke Liu is a prominent inventor based in Cambridge, MD (US), known for his significant contributions to the field of medical research. He holds 3 patents that focus on innovative treatments for lysosomal storage disorders. His work has the potential to impact the lives of many patients suffering from these complex conditions.

Latest Patents

One of Ke Liu's latest patents involves the use of delta tocopherol for the treatment of lysosomal storage disorders. This disclosure outlines a novel application of delta tocopherol in addressing diseases related to lysosomal storage disorders. The patent includes methods for modulating cholesterol recycling and addresses conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease, and Tay Sachs disease. Additionally, the patent describes a method for treating these disorders through the administration of delta tocopherol, both alone and in combination with cyclodextrin.

Career Highlights

Ke Liu is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research that aims to improve treatment options for patients with lysosomal storage disorders.

Collaborations

Throughout his career, Ke Liu has collaborated with notable colleagues, including Wei Ping Zheng and Juan Jose Marugan. These partnerships have fostered a collaborative environment that enhances the research and development of innovative treatments.

Conclusion

Ke Liu's contributions to the field of lysosomal storage disorders through his patents and research at the National Institutes of Health highlight his dedication to improving patient outcomes. His innovative approaches have the potential to change the landscape of treatment for these challenging conditions.